Search Results

There are 5804 results for: content related to: Galantamine attenuates reinstatement of cue-induced methamphetamine-seeking behavior in mice

  1. Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease

    The Journal of Clinical Pharmacology

    Volume 46, Issue S1, July 2006, Pages: 17S–26S, Dr George T. Grossberg, Dr Keith R. Edwards and Dr Qinying Zhao

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006288735

  2. Steady-State Pharmacokinetics of Galantamine Are Not Affected by Addition of Memantine in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 45, Issue 5, May 2005, Pages: 519–528, Dr Caiping Yao, Dr Arash Raoufinia, Dr Michael Gold, Dr Jeffrey S. Nye, Dr Steven Ramael, Mr Mukund Padmanabhan, Dr Yolande Walschap, Dr Tom Verhaeghe and Dr Qinying Zhao

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270005274551

  3. You have free access to this content
    Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease

    CNS Drug Reviews

    Volume 8, Issue 2, June 2002, Pages: 159–176, Sean Lilienfeld

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2002.tb00221.x

  4. Galantamine for Alzheimer's disease and mild cognitive impairment

    Intervention Review

    The Cochrane Library

    Clement Loy and Lon Schneider

    Published Online : 25 JAN 2006, DOI: 10.1002/14651858.CD001747.pub3

  5. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons

    European Journal of Neuroscience

    Volume 29, Issue 3, February 2009, Pages: 455–464, Joana B. Melo, Carla Sousa, Pedro Garção, Catarina R. Oliveira and Paula Agostinho

    Version of Record online : 2 FEB 2009, DOI: 10.1111/j.1460-9568.2009.06612.x

  6. Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 42, Issue 4, April 2002, Pages: 428–436, Qinying Zhao, Ganesh R. Iyer, Tom Verhaeghe and Luc Truyen

    Version of Record online : 8 MAR 2013, DOI: 10.1177/00912700222011481

  7. Galantamine Pharmacokinetics, Safety, and Tolerability Profiles Are Similar in Healthy Caucasian and Japanese Subjects

    The Journal of Clinical Pharmacology

    Volume 42, Issue 9, September 2002, Pages: 1002–1010, Dr. Qinying Zhao, Mr. Martin Brett, Dr. Nancy van Osselaer, Dr. Fenglei Huang, Dr. Alain Raoult, Dr. Achiel van Peer, Dr. Tom Verhaeghe and Dr. Rita Hust

    Version of Record online : 19 MAR 2013, DOI: 10.1177/009127000204200907

  8. You have free access to this content
    Nicotinic Cholinergic Modulation: Galantamine as a Prototype

    CNS Drug Reviews

    Volume 8, Issue 4, December 2002, Pages: 405–426, Diana S. Woodruff-Pak, Cynthia Lander and Hugo Geerts

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2002.tb00237.x

  9. Galantamine for vascular cognitive impairment

    Intervention Review

    The Cochrane Library

    Jacqueline Birks and David Craig

    Published Online : 25 JAN 2006, DOI: 10.1002/14651858.CD004746.pub2

  10. Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations

    The Journal of Clinical Pharmacology

    Volume 43, Issue 5, May 2003, Pages: 514–523, Vladimir Piotrovsky, Achiel Van Peer, Nancy Van Osselaer, Martin Armstrong and Jeroen Aerssens

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003251853

  11. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery

    Journal of Pharmaceutical Sciences

    Volume 94, Issue 8, August 2005, Pages: 1736–1746, Alexis Kays Leonard, Anthony P. Sileno, Conor MacEvilly, Charles A. Foerder, Steven C. Quay and Henry R. Costantino

    Version of Record online : 28 JUN 2005, DOI: 10.1002/jps.20389

  12. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

    International Journal of Geriatric Psychiatry

    Volume 19, Issue 1, January 2004, Pages: 58–67, Roy W. Jones, Hilkka Soininen, Klaus Hager, Dag Aarsland, Peter Passmore, Anita Murthy, Richard Zhang and Ranbir Bahra

    Version of Record online : 5 JAN 2004, DOI: 10.1002/gps.1038

  13. You have full text access to this OnlineOpen article
    Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen

    International Journal of Clinical Practice

    Volume 60, Issue 5, May 2006, Pages: 533–540, N. Thavichachart, 1 K. Phanthumchinda, 2 S. Chankrachang, 3 R. Praditsuwan, 4 S. Nidhinandana, 5 V. Senanarong and 6 N. Poungvarin 6

    Version of Record online : 2 MAY 2006, DOI: 10.1111/j.1368-5031.2006.00892.x

  14. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease

    Psychogeriatrics

    Volume 16, Issue 2, March 2016, Pages: 121–134, Mizuki Oka, Shutaro Nakaaki, Atsushi Negi, Jun Miyata, Atsuo Nakagawa, Nobutsugu Hirono and Masaru Mimura

    Version of Record online : 26 JUN 2015, DOI: 10.1111/psyg.12132

  15. You have free access to this content
    Effect of galantamine on the human α7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity

    British Journal of Pharmacology

    Volume 145, Issue 5, July 2005, Pages: 672–678, Laura Texidó, Esteve Ros, Mireia Martín-Satué, Susana López, Jordi Aleu, Jordi Marsal and Carles Solsona

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706221

  16. Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together

    The Journal of Clinical Pharmacology

    Volume 42, Issue 12, December 2002, Pages: 1341–1351, Dr. Fenglei Huang, Dr. Kenneth C. Lasseter, Mr. Luc Janssens, Dr. Tom Verhaeghe, Dr. Henry Lau and Dr. Qinying Zhao

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270002042012005

  17. The effects of galantamine treatment on caregiver time in Alzheimer's disease

    International Journal of Geriatric Psychiatry

    Volume 18, Issue 10, October 2003, Pages: 942–950, Mary Sano, Gordon K. Wilcock, Bart van Baelen and Shane Kavanagh

    Version of Record online : 25 SEP 2003, DOI: 10.1002/gps.1000

  18. You have free access to this content
    THE EFFECT OF GALANTAMINE ON THE BLOOD PRESSURE OF THE RAT

    British Journal of Pharmacology and Chemotherapy

    Volume 26, Issue 2, February 1966, Pages: 295–301, M. CHRUSCIEL and V. VARAGIĆ

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1476-5381.1966.tb01908.x

  19. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells

    Journal of Pineal Research

    Volume 49, Issue 2, September 2010, Pages: 141–148, Alejandro Romero, Javier Egea, Antonio G. García and Manuela G. López

    Version of Record online : 1 JUN 2010, DOI: 10.1111/j.1600-079X.2010.00778.x

  20. Galantamine, a Novel Treatment for Alzheimer's Disease: A Review of Long-term Benefits to Patients and Caregivers

    Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics

    Pierre Tariot, Bengt Winblad, Pages: 705–723, 2002

    Published Online : 18 APR 2002, DOI: 10.1002/0470846453.ch66